The TricValve is a percutaneous treatment system that involves implanting 2 valves into the superior and inferior veins that drain into the heart. During severe tricuspid valve regurgitation (TR), the back flow of blood into the right atrium and into the veins impede the proper flow of returning blood back into the heart. This leads to a state of severe congestion. Patient would feel symptoms of swelling of the legs, belly and will also lose appetite. Overtime, the upper body would also become congested and the veins in the neck become prominent. Later stages of this condition include liver and kidney failure leading to reduced survival. (Figure 1)
When the 2 valves of the TricValve system are implanted, these valves prevent the pressure of the regurgitant jet from entering the veins and shields the organs from the regurgitation. Research data has shown that this treatment translate to reduced symptoms for patients with severe TR (figure 2)
Reference
1: Estévez-Loureiro R, Sánchez-Recalde A, Amat-Santos IJet al. 6-Month Outcomes of the
TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO
Study. JACC Cardiovasc Interv. 2022 Jul 11;15(13):1366-1377. doi:
10.1016/j.jcin.2022.05.022. Epub 2022 May 17. PMID: 35583363.